Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2078-2099

  Giordano, Sharon H ^a   Temin, Sarah ^c   Kirshner, Jeffrey J ^d   Chandarlapaty, Sarat ^e   Crews, Jennie R ^g   Davidson, Nancy E ^h   Esteva, Francisco J ^f   Gonzalez Angulo, Ana M ^a   Krop, Ian ⁱ   Levinson, Jennifer ^j   Lin, Nancy U ⁱ   Modi, Shanu ^e   Patt, Debra A ^b   Perez, Edith A ^k   Perlmutter, Jane ^j   Ramakrishna, Naren ^l   Winer, Eric P ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS ONCOLOGY   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d Hematology Oncology Associates of Central New York   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g PeaceHealth St Joseph Medical Center   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j Mayo Clinic ^*

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF FLORIDA HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB EMTANSINE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; EVIDENCE BASED PRACTICE; HORMONAL THERAPY; HUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; MAYTANSINE; MOLECULAR TARGETED THERAPY; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOCIETIES, MEDICAL; TAXOIDS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84905842097     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.0948     Document Type: Article

References (52)

1. American Society of Clinical Oncology: Breast cancer. http://www.cancer.net/cancer-types/breast-cancer
2. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
3. Ramakrishna N, Temin S, Chandarlapaty S, et al: Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2100-2108, 2014
4. Members of the Breast Cancer Disease Site Group: The role of trastuzumab (Herceptin) in the treatment of women with HER2/neu-overexpressing metastatic breast cancer. Madarnas Y, Tey R, reviewers. Toronto (ON): Cancer Care Ontario; 2011 Sep 15 [Endorsed 2010 Jun 11]. Program in Evidence-based Care Evidence-Based Series No.: 1-15 Version 3
5. Madarnas Y, Haynes AE, Eisen A: The continued use of trastuzumab beyond disease progression in patients with metastatic breast cancer. Toronto (ON): Cancer Care Ontario; 2009 Aug 17. Committee to Evaluate Drugs/Cancer Care Ontario Subcommittee: Special Advice Report #13
6. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
7. Huober J, Fasching PA, Barsoum M, et al: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer: Results of the eLEcTRA trial. Breast 21:27-33, 2012
8. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
9. Schwartzberg LS, Franco SX, Florance A, et al: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15:122-129, 2010
10. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
11. Blackwell KL, Miles D, Gianni L, et al: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30:5s, 2012 (suppl; abstr LBA1)
12. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
13. Andersson M, Lidbrink E, Bjerre K, et al: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol 29:264-271, 2011
14. Valero V, Forbes J, Pegram MD, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2 gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 29:149-156, 2011
15. Inoue K, Nakagami K, Mizutani M, et al: Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: The JO17360 Trial Group. Breast Cancer Res Treat 119:127-136, 2010
16. Gelmon KA, Boyle F, Kaufman B, et al: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30, 2012 (suppl; abstr LBA671)
17. Cameron D, Casey M, Oliva C, et al: Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. Oncologist 15:924-934, 2010
18. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
19. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
20. Blackwell KL, Burstein HJ, Storniolo AM, et al: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study. J Clin Oncol 30:2585-2592, 2012
21. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
22. Guarneri V, Lenihan DJ, Valero V, et al: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 24:4107-4115, 2006 (Pubitemid 46622286)
23. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
24. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27:1999-2006, 2009
25. von Minckwitz G, Vogel P, Schmidt M, et al: Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer: The TBP study (GBG 26 / BIG 3-05). Presented at the 30th San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 4056)
26. von Minckwitz G, Zielinski C, Maarteense P, et al: Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26:47s, 2008 (suppl; abstr 1025)
27. Tripathy D, Slamon DJ, Cobleigh M, et al: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063-1070, 2004 (Pubitemid 41095039)
28. Wildiers H, Kim SB, Gonzalez-Martin A, et al: T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. Presented at the European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013 (abstr LBA15)
29. Swain SM, Kim SB, J. C., et al: Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized, double-blind, placebo controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 72, 2012 (suppl 3; abstr P5-18-26)
30. Maxwell C: Quality-of-life considerations with taxane-based therapy in metastatic breast cancer. Clin J Oncol Nurs 17:35-40, 2013 (suppl)
31. National Cancer Institute: Breast cancer treatment (PDQ): Stage IIIB, inoperable IIIC, IV, recurrent, and metastatic breast cancer - Ado-trastuzumab emtansine. http://www.cancer.gov/cancertopics/pdq/treatment/breast/ healthprofessional/page7#Section-883
32. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138-1144, 2010
33. O'Shaughnessy J, Blackwell KL, Burstein H, et al: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26:44s, 2008 (suppl; abstr 1015)
34. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002 (Pubitemid 34273269)
35. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
36. Fagerlin A, Zikmund-Fisher BJ, Ubel PA: Helping patients decide: Ten steps to better risk communication. J Natl Cancer Inst 103:1436-1443, 2011
37. Butow PN, Dowsett S, Hagerty R, et al: Communicating prognosis to patients with metastatic disease: What do they really want to know? Support Care Cancer 10:161-168, 2002 (Pubitemid 36056313)
38. Hagerty RG, Butow PN, Ellis PA, et al: Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721-1730, 2004 (Pubitemid 41079812)
39. Lux MP, Bayer CM, Loehberg CR, et al: Shared decision-making in metastatic breast cancer: Discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. Breast Cancer Res Treat 139:429-440, 2013
40. Silber JH, Rosenbaum PR, Clark AS, et al: Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389-397, 2013
41. Al-Abbadi MA, Washington TA, Saleh HA, et al: Differential expression of HER-2/NEU receptor of invasive mammary carcinoma between Caucasian and African American patients in the Detroit metropolitan area: Correlation with overall survival and other prognostic factors. Breast Cancer Res Treat 97:3-8, 2006
42. Elledge RM, Clark GM, Chamness GC, et al: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86:705-712, 1994 (Pubitemid 24138977)
43. Kurian AW, Fish K, Shema SJ, et al: Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 12:R99, 2010
44. Patel TA, Colon-Otero G, Bueno Hume C, et al: Breast cancer in Latinas: Gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist 15:466-475, 2010
45. Sparano JA, Wang M, Zhao F, et al: Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406-414, 2012
46. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, Commonwealth Fund, 2008
47. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD, National Cancer Institute, 2012
48. Centers for Disease Control and Prevention: United States cancer statistics: 1999-2008 cancer incidence and mortality data. www.cdc.gov/uscs
49. American Cancer Society: Cancer facts and figures for African Americans 2011-2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-027765.pdf
50. American Geriatrics Society Expert Panel on the Care of Older Adults With Multimorbidity: Patient-centered care for older adults with multiple chronic conditions: A stepwise approach from the American Geriatrics Society. J Am Geriatr Soc 60:1957-1968, 2012
51. Esteva FJ, Yu D, Hung MC, et al: Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7:98-107, 2010
52. Morrow PK, Wulf GM, Ensor J, et al: Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29:3126-3132, 2011